This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

JUL 2 2 2002

PTO/SB/04-7 (10-01)
Approved for use through 10/31/2002. OME 0551-003
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

no persons are required to respond to a collection of information unless it contains a party OMB

Under the Paperwork Reduction Act of control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Co	omplete if Known	型
Application Number	09/974.519	方
Filing Date	10/10/2001	9
First Named Inventor	Dhiren R. Thakker	72
Art Unit	1619	8
Examiner Name		0
Attorney Docket Number	421/32/2	

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials*		Document Number Number - Kind Code 2 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
1	1	US-4,199,507	04/22/1980	Hoeksema	
11	2	US- 5,011,234	03/19/1991	Bundy et al.	
01	3	US- 5,144,045	09/01/1992	Wissner et al.	
1	4	US- 5,208,223	05/04/1993	Wissner et al.	C -
	5	US- 5,306,830	04/26/1994	Andersson et al.	
	6	US- 5,334,712	08/02/1994	Johnson et al.	<u>₩ ⊆ </u>
	7	US- 5,360,815	11/01/1994	Fortin et al.	2 - (
	8	US- 5,373,095	12/13/1994	Johnson et al.	
	9	US- 5,430,050	07/04/1995	Ohtsuka et al.	2 4
	10	US- 5,519,163	05/21/1996	Gibbs et al.	8 20
	11	US- 5,580,956	12/03/1996	Saito et al.	
	12	US- 5,942,246	08/24/1999	Mayhew et al.	0/290
		US-			8 4
		US-			
V		US-			
		US-			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code3 -Number ⁴ -Kind Code ⁵ (#known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶		
9	13	WO 98/10776		Shanahan-Prenderga				
						_		
J								

-				
	Examiner Signature	m	Date Considered	9/03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

RADEMAN Under the Paperwork Reduction control number. Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

(use as many sheets as necessary) of

ns are requ	Approved fo U.S. Patent and Trademark Ofi ired to respond to a collection of	PTO/SB, r use through 10/31/2002. OM fice: U.S. DEPARTMENT OF 6 information unless it contains	(100 (100) B (00) 1-0 COMMER a valid (0	-01) 1031 RCE DMB	PAC	
	Co.	mplete if Known	Z			
une l	Application Number	09/974.519	品	3		
URE	Filing Date	10/10/2001	0.	á		
ANT	First Named Inventor	Dhiren R. Thakker		2		
7111	Group Art Unit	1619	m ·	2		
_	Examiner Name		<u> </u>	3]()	
	Attorney Docket Number	421/32/2	<u> </u>		/m	
NON P	ATENT LITERATURE DO	CUMENTS	66	1 200	ı≅	
journal, seria	L LETTERS), title of the article (val, symposium, catalog, etc.), dather, city and/or country where pul	e, page(s), volume-issue	/2900	ا ر	Ü	
J. Bublist	TOTAL STATE OF STATE					

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	Ţ
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	See Attac		
1	15	BLEASDALE, J.E. ET Al., "Inhibition of Phospholipase C Dependent Processes by U-73,122," Advances in Prostaglandin, Thromboxane, and Leukotriene Research, p. 590-593, (July 17, 1989).	
J_1	16	PERRELLA, FRANK W., ET AL., "Phospholipase C Inhibitors: A New Class of Cytotoxic Agents," J. Med. Chem., p. 2232-2237, (July 17, 1994).	
	17	CEREIJIDO, M., ET AL., "The making of a tight junction," Journal of Cell Science, p. 127-132, (July 17, 1993).	
	18	TOMITA, MIKIO ET AL., "Absorption-Enhancing Mechanism of Sodium Caprate and Decanoylcarnitine in Caco-2 Cells," The Journal of Pharmacology and Experimental Therapeutics, p. 739-743, (July 17, 1995).	
1	19	LINDMARK, TUULIKKI ET AL., "Absorption Enhancement through Intracellular Regulation of Tight Junction Permeability by Medium Chain Ftty Acids in Caco-2 Cells," The Journal of Pharmacology and Experimental Therapeutics, p. 362-369, (July 17, 1998).	

Date Examiner Signature Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Information Disclosure Statement by Applicant (PTO/SE/08B), Additional Other Prior Art - Non Patent Literature Documents

Attachment 1

14 a.

WALLACH, DONALD P., ET AL., "Studies on the Arachidonic Acid Cascade-I Inhibition of Phospholipase A2 in vitro and in vivo by Several Novel Series of Inhibitor Compounds," Biochemical Pharmacology, Vol. 30 (No. 11), p. 1315-1324, (July 17, 1981).

c.





Sheet 1 of 2

FORM PTO-	, 1449 U.S.	Department of Comm	ne ce		Attorn Tropol	ENTER 160	FF 5500	Serial No.
Patent and T	rademark	Office MAY 2 9 2000	3 3					09/974,519
List of Docun	nents Cited	d by Applicant	S)					
					Applicant(s): Thakke	r et al.	
					Filing Date:	October	20, 2001	Group 1619
			U.S. PA	TENT D	OCUMENTS	3		
Examiner Initial						Subclass	Filing date if Appropriate	
		F	OREIGN I	PATENT	DOCUMEN	NTS		
		Document Number	Date	C	Country Name of Patentee or Applicant		Translation Yes No	
$\overline{\Lambda}$	1.	02 11666 A2	02/14/02	wo	D-Pharm Ltd.		Ltd.	Yes
	ОТ	HER DOCUMEN	ΓS (Includir	ng Autho	or, Title, Date	e, Pertinen	t Pages, Etc	.)
Liu et al., Dodecylphosphocoline-Mediated Enhancement of Paracellular Permeability and Cytotoxicity of Caco-2 Cell Monolayers, Journal of Pharmaceutical Sciences, 88(11):1161-1168 (November 1999).								
}	3. Pawelcyzk et al., Inhibition of Phospholipase Cδ by Hexadecylphosphorylcholine and Lysophospholipids with Antitumor Activity, Biochemical Pharmacology, 45 (2):493-497 (1993).							
	4. Berkovic et al., Hexadecylphosphorylcholine Inhibits Phosphatidylinositol and Phosphatidylcholine Phospholipase C in Human Leukemia Cells, Journal of Experimental Therapeutics & Oncology, 1:302-311 (1996).							
- 0							1	

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAY 2 9 2003 W

.... R.



Sheet 2 of 2

P 1"" 5/	ECH CENTED TODOLEGY	
FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 421/32/2	Serial No.
Patent and Trademark Office		09/974,519
List of Documents Cited by Applicant		
	Applicant(s): Thakker et al.	
	Filing Date: October 20, 2001	Group 1619

	ОТ	HER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
1	5.	Grunicke et al., <i>Inhibition of Phospholipase C and Protein Kinase C by Alkylphosphocholines</i> , <u>Drugs of Today</u> , 34 (F):3-14 (December 1998).
	6.	Hashimoto et al., Effects of β-Lactoglobulin on the Tight-junctional Stability of Caco-2-SF Monolayer, Bioscience Biotechnol. Biochem., 62 (9)1819-1821 (1998).
	7.	Cereijido et al., <i>The Making of a Tight Junction</i> , <u>Journal of Cell Science</u> , Suppl. 17 :127-132 (1993).
	8.	Hilgard et al., Alkylphosphocholines: A New Class of Membrane-Active Anticancer Agents, Cancer Chemotherapy and Pharmacology, 32 :90-95 (1993).
	9.	Hilgard et al., Inhibitors of Signal Transduction: The Alkylphosphocholines, Drug News Perspectives, 12 (2):69-72 (March 1999).
	10.	Ward et al., Phospholipase C-y Modulates Epithelial Tight Junction Permeability Through Hyperphosphorylation of Tight Junction Proteins, The Journal of Biological Chemistry, 277(38):35760-35765 (September 20, 2002).
	11.	Cereijido et al., Molecular Physiology and Pathyphysiology of Tight Junctions: I. Biogenesis of Tight Junctions and Epithelial Polarity, American Journal of Physiology, 279(3):G477-G482 (2000).
4	12.	Gasbarrini et al., Structure and Function of Tight Junctions. Role in Intestinal Barrier, Italian Journal of Gastroenterology and Hepatology, 31 (6):481-488 (August 1999).

EXAMINER	DATE CONSIDERED	9/	03
· · · · · · · · · · · · · · · · · · ·		,	

^{*}Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applict.